Partnership advances patient access to precision cancer care through leading scientific innovation in molecular research
IRVING, Texas, March 26, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has become the 26th leading cancer center to join the Precision Oncology Alliance™. The Alliance is a collaborative network of leading cancer centers that is developing standards of care and best practices for the application of tumor molecular profiling to make cancer treatment more precise and effective.
“Sylvester Comprehensive Cancer Center is well recognized as a leader in cancer care, and we are delighted to add its expertise to the growing Precision Oncology Alliance,” said Brian J. Brille, Vice Chairman of Caris Life Sciences.
Through the Precision Oncology Alliance, the South Florida cancer center will actively participate in collecting molecular data and longitudinally tracking outcomes data for patients who have their tumors profiled with the Caris Molecular Intelligence® platform. In addition, as a member of the Precision Oncology Alliance, Sylvester Comprehensive Cancer Center has the opportunity to contribute and publish data and participate in clinical trials collaboration to validate Next Generation Profiling™ (NGP), Caris’ proprietary machine learning algorithms to improve patient diagnosis and treatment selection.
“Over the past several years we have increased our phase 1 program, our immunotherapy research and our epigenetic-targeted therapeutic approaches. We serve a very diverse and ever-increasing population of cancer patients and those at risk for cancer. This relationship will ensure and accelerate our focus on individualized treatment and precision medicine,” said Stephen Nimer, M.D., Director, Sylvester Comprehensive Cancer Center. “We look forward to working with Caris and the other members of the Precision Oncology Alliance to collectively advance and provide greater patient access to precision cancer care, and continue to make significant gains along every measure of clinical and operational excellence.”
Michael Korn, M.D., Chief Medical Officer at Caris Life Sciences, added, “The Sylvester Comprehensive Cancer Center is dedicated to applying the latest in cancer research to patient care, rigorously evaluating effectiveness of new treatments, and offering treatment approaches rooted in new clinical trial opportunities. The Precision Oncology Alliance will benefit from the institution’s engagement and focus on diversity.”
The Precision Oncology Alliance is comprised of 26 academic, hospital and community-based cancer institutions, including seven National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. The member institutions work together to broaden patient access to precision cancer care and establish evidence-based standards for tumor profiling and molecular testing in oncology, and to validate and assess the company’s NGP offerings. Leveraging the comprehensive genomic and proteomic tumor profiling services available through the Caris Molecular Intelligence® platform, Precision Oncology Alliance members can identify therapy options and clinical trial opportunities based on the unique molecular characteristics of a patient’s tumor. The results help inform treatment decisions, fulfilling the promise of precision medicine.
About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Caris is also advancing precision medicine with Next Generation Profiling™ that combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System™, with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).